

State of Oklahoma SoonerCare Xpovio[®] (Selinexor) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	1
Pharmacy billing (NDC:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Inforn	nation
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
	Prescriber Informat	tion
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
 Multiple Myeloma A. Is diagnosis relap B. Is disease refractor ≥2 immunomodula C. Will selinexor be under the following of the company of the company	sived ≥2 prior lines of systemic therapsed or refractory multiple myeloma? ory after ≥4 prior therapies including atory agents, and an anti-CD38 monused in combination with dexamethas	Yes No ≥2 proteasome inhibitors (PIs), oclonal antibody? Yes No sone? Yes No
3. Has the member experience If yes, please specify adverse	ridence of progressive disease while ced adverse drug reactions related to reactions:	o selinexor therapy? Yes No
Prescriber Signature: I certify that the indicated tre best of my knowledge. Please complete this form in full will resu	e do not send in chart notes. Specific inf	Date: od all information is true and correct to the formation will be requested if necessary. Failure to

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.